TrialThe oncologist2019

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.

Daniel L Suzman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.